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Abstract
Background: Gadolinium nanoparticles (Gd-NP) combined with radiotherapy are
investigated for radiation dose enhancement in radiotherapy treatment. Indeed, NPs
concentrated in a tumor could enhance its radiosensitization. The noninvasive
quantification of the NP concentration is a crucial task for radiotherapy treatment
planning and post-treatment monitoring as it will determine the absorbed dose. In this
work, we evaluate the achievable accuracy of in vivo SPECT-based Gd-NP organ
concentration on rats.
Methods: Gd-NPs were labeled with 111In radionuclide. SPECT images have been
acquired on phantom and rats, with various Gd-NP injections. Images have been
calibrated and corrected for attenuation, scatter, and partial volume effect. Image-based
estimations were compared to both inductively coupled plasma mass spectrometer
(ICP-MS) for Gd concentration and ex vivo organ activity measured by gamma counter.
Results: The accuracy for the Gd mass measurements in organ was within 10% for
activity above 2 MBq or concentrations above ∼ 3–4 MBq/mL. The Gd mass calculation
is based on In-Gd coefficient which defines the Gd detection limit. It was found to be in
a range from 2 mg/MBq to 2 μg/MBq depending on the proportions of initial injection
preparations. Measurement was also impaired by free Gd and 111In formed during
metabolic processes.
Conclusions: Even if SPECT image quantification remains challenging mostly due to
partial volume effect, this study shows that it has potential for the Gd mass
measurements in organ. The main limitation of the method is its indirectness, and a
special care should be taken if the organ of interest could be influenced by different
clearance rate of free Gd and 111In formed by metabolic processes. We also discuss the
practical aspects, potential, and limitations of Gd-NP in vivo image quantification with a
SPECT.
Keywords: SPECT, Quantification, AGuIX, Nanoparticles, in vivo
Introduction
The use of nanoparticles (NP) in radiotherapymay help to enhance the dose ratio between
a tumor and healthy tissues [1]. The nanoparticles based on high-Zmetals are delivered to
a tumor and generate a localized absorbed dose enhancement within the target volume.
Indeed, it has been shown on simulations that when the X-ray beam hits densely packed
gold NPs, the photoelectric effect increases, leading to the emission of additional elec-
trons depositing their energy locally [2]. It has been proposed to use Gd nanoparticles for
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tumor radiosensitization [3, 4]. Many research and industrial groups are actively work-
ing on this subject [1, 5, 6]. However, despite good in vitro results, in vivo performances
are still controversial and actively investigated. Two of the main concerns are the in vivo
localization and the quantification of the NP. These are crucial tasks to determine the
delivered dose for radiotherapy treatment as radiosensitization would change the optimal
dose to deliver.
In the past two decades, the main effort was either on only qualitative in vivo imaging
or in vitro/ex vivo quantification of NPs. For example, inductively coupled plasma mass
spectrometer (ICP-MS) techniques [7] can provide quantitative elemental composition
with sensitivity of 1 ng/L [8]. The ICP-MS detects ions distinguished by their mass-to-
charge ratio in incinerated samples, and therefore, it provides destructive tests and cannot
be used in vivo. Optical imaging [9] offers high sensitivity and uses non-ionizing radiation
but low penetration depth. Moreover, this method is non-quantitative for in vivo imaging
studies [9].
Magnetic resonance imaging (MRI) seems to be a good candidate for localization and
quantification of metal NPs, particularly gadolinium NPs (Gd-NPs) [10]. It has a high
image resolution and excellent soft tissue contrast. The Gd contrast agents are widely
used to improveMRI images. However, due to nonlinear correlation between the contrast
agent concentration in tissue and the MRI signal, in vivo quantification remains challeng-
ing. A recent study [10] shows that the protocol for quantitative MRI should take into
account the age of the patients and their diagnoses. It is also prudent to keep the MR field
strength constant and the same T1 weighted sequence for all patients. Moreover, one of
the major limitation of MRI is a lack of sensitivity for low concentration of Gd [10].
The radionuclide-based imaging such as positron emission tomography (PET) com-
bined with MRI was also tested for image-guided radiation therapy [11]. The Gd-NPs
can be radiolabeled with 68Ga (T1/2 = 68 min) tracer and, thus, be detected and quanti-
fied from PET images. However, the authors of [11] only provided qualitative assessment
for PET images without quantitative image analysis. Another nuclear medicine tech-
nique that could be used is single photon emission computed tomography (SPECT) where
the Gd-NPs could be labeled with 111In (T1/2 = 2.8 days) tracer. Even if PET quan-
tification might be easier to implement, SPECT image quantification [12–14] is also
possible. Widely available in clinic, β+ emitters (18F, 68Ga) have relatively short half-life
(T1/2 = 110 min and T1/2 = 68 min) compared to 111In. Other β+ emitters such as 64Cu
or 89Zr have longer half-life but are not always available. Here, we focus on SPECT with
111In, which was the only available modality at our disposal.
In this work, we aim to quantify the in vivo Gd concentration distribution of AGuIX
Gd-NPs [6] labeled with 111In from SPECT images. Image-based estimations were per-
formed on phantoms, rats kidneys, and chondrosarcomas tumors. Obtained values were
compared to ICP-MS measurements. The main steps are described in the “Method and
materials” section, followed by results and discussion as well as difficulties that could be
avoided in future similar researches.
Method andmaterials
General workflow
The quantification of Gd mass in organ from SPECT images is an indirect process, see
Fig. 1. First, the 111In concentration in a volume of interest (in red in Fig. 1) was estimated
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Fig. 1 Main steps of the analysis. Schematic representation of the main steps of the analysis
from images that were calibrated and corrected by scatter, attenuation, and partial volume
effect. An 111In to Gd factor αInGd was estimated and applied to derive the corresponding
Gd mass. Obtained values were compared for activity to reference gamma counter and
for Gdmass to ICP-MSmeasurements. Studies were performed on both phantom and rat
images acquired on a preclinical SPECT/CT device.
Nanoparticle radiolabeling
The AGuIX nanoparticles used in this study were obtained from NHTheraguix (Crolles,
France). They are composed of a polysiloxane matrix bearing DOTA chelators on the
surface able to chelate Gd3+ ions and 111In for SPECT experiments. The AGuIX NP
hydrodynamic diameter is under 6 nm. The nanoparticles (50μL, 100 mM) were radi-
olabeled by adding 300 μL of citrate buffer 50 mM pH5 and 40–80 MBq of high
purity 111In-chloride (Mallinckrodt, Petten, Netherlands). The mixture was incubated
for 30 min at 40 ◦C. A diethylenetriaminepentaacetic acid (DTPA) was added at the
end of radiolabeling after incubation for free 111In evacuation. Radiochemical purity of
AGuIX-111In was over 97%.
For stability testing, an aliquot of the radiolabelled AGuIX-111In was incubated at 37°C
in 2mL phosphate buffer saline (pH 7.4) and in rat serum, and radiochemical purity (RCP)
was evaluated using ITLC-SG and citrate buffer 0.1M pH5 as mobile phase. This test
showed that at 48h after incubation, RCP was still greater than 96% in phosphate buffer
saline (pH 7.4) and in rat serum indicating a suitable kinetic stability to perform in vitro
and in vivo experiments.
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Phantoms and animals
For the in vitro studies, two sets of data were analyzed:
• 111In + Gd-NPs. Four tubes were used, containing 500 μL of saline solution with
different concentrations of Gd-NPs labeled with 111In corresponding to 7.46 MBq,
4.20 MBq, 2.16 MBq, and 1.23 MBq at the SPECT imaging time. They were used to
measure the Gd mass (described below).
• 111In without Gd-NPs. Six tubes were imaged, containing 250 μL of 111In
corresponding to 9.85 MBq, 4.55 MBq, 2.50 MBq, 1.27 MBq, 0.67 MBq, and
0.37 MBq at the SPECT imaging time. The aim of this experiment was to evaluate the
linearity of the image-based quantification for different activities.
For in vivo imaging, 9 OFA (Oncins France Strain A) male rats with chondrosarcomas
were used, four weeks after tumor placement. The animals were injected both intratu-
morally or intravenously with an 111In radiolabeled Gd-NPs in the presence of DTPA,
with activities ranging from 5 to 25 MBq measured for each injection with a dose cali-
brator (Capintec Inc., Florham Park, USA). Animals were sacrificed at 5 min and 30 min
intratumorally and 1, 2, and 4 h for intravenously injected animal. The original study plan
included measurements at 6H and at 24H. Even if the injected activity was not low (10–
20 MBq), only the image obtained at 4H were usable while the signal-to-noise ratio of the
others was insufficient. We also stop at 4H point because the full irradiation study, that is
under publication, showed that the treatment is effective at this time point. Images were
acquired post mortem in order to have reference measurements on extracted organs. Kid-
neys and tumors were removed and placed in formol in plastic tubes adapted for a gamma
counter measurement of the activity. Supplementary images were also acquired on these
tubes for ex vivo studies.
SPECT/CT image acquisition
We used a nanoSPECT/CT (Bioscan Inc., Washington D.C., USA) for preclinical imaging
with multiplexing multipinhole apertures. It has four detection heads allowing the acqui-
sition of four projections simultaneously. The pinhole collimator for rat imaging used in
the experiments, named APT2, has 9 cone shape pinholes drilled from both sides of the
collimator giving an opening diameter of 2.5 mm. The field of view of the camera is a
cylinder with a diameter of 65 mm, and the axial scan length of 25 mm. We used 111In
radionuclide emitting 171.3 keV (90.61%) and 245.4 keV (94.12%) gamma rays. Therefore,
the projections were acquired for two energy windows of 10% around the peaks and one
additional energy window of 209 keV ± 10% used for scatter correction.
The SPECT device acquired 24 projections (6 projections × 4 heads) of 256×256 pixels
for every 15 degrees. The scan duration was 100 seconds per projection. The reconstruc-
tion was performed with the manufacturer software, HiSPECT, using an ordered subsets
expectation maximization (OSEM) algorithm with 9 iterations and 4 subsets with an
image voxel size of 0.6 mm.
The cone-beam CT scans contained 180 projections for the full coverage with a
duration of 1 s/projection acquired with a beam voltage of 55 kV. The images were recon-
structed with Feldkamp’s filtered backprojection reconstruction algorithm [15] with a
voxel size of 0.4 mm. The reconstructed CT images were registered and resampled in
order to match the sampling of the SPECT images.
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SPECT image corrections
Scatter
The dual-energy correctionmethod (DEW) [16] was used for the scatter corrections. This
method consists in subtracting an estimate of the scatter component from the peaks. It
is based on a measurement of the number of counts in one energy region near the peak.
The two peaks, 171.3 keV and 245.5 keV, were corrected for the scatter component based
on the number of counts in the scatter window between these peaks.
Attenuation
The reconstructed SPECT images were corrected with Chang’s multiplicative method
[17] on a voxel-by-voxel basis. The linear attenuation coefficient images were recalcu-
lated from CT images using a bilinear model (see [18]) and based on the NIST tables of
mass attenuation coefficients. The attenuation correction factors (ACF) for each voxel of
the reconstructed image were obtained taking into account the gamma path through the
tissue.
The 111In isotope has two photopeaks which means that the attenuation correction
should be done for these two peaks separately. However, the comparison between the
correction for two peaks simultaneously and separately gave a difference of ∼ 1%. There-
fore, we applied the attenuation corrections in the two energy windows by calculating
a weighted combination of the ACFs with experimentally defined weights for each peak
component as w171keV = 0.635 and w245keV = 0.365.
Partial volume effect
SPECT images suffer from PVEs due to limited spatial sampling and a finite spatial
resolution [19]. Therefore, a region of high activity tends to be underestimated and neigh-
boring voxels overestimated. This means that if the VOI is selected from an anatomic CT
image, the measured activity will be biased (underestimated in this case). In this study, we
used post-reconstruction Müller-Gärtner method (MGM) [20] for partial volume effect
correction in its generalization to two regions (see [21] for the detailed workflow).
Absolute calibration
For NanoSPECT/CT image calibration, we followed the NEMA standard protocol [22].
We used a cylindrical phantom with 5-mL volume containing the activity with a con-
centration of cVol = 0.72 ± 0.01 kBq/mL measured with a gamma counter (Wallac
Wizard 1470 Gamma Counter, GMI inc.) and recalculated for the acquisition time. The
calibration system volume sensitivity, SVol [23] (in cps/Bq), was calculated as:
SVol= RcVol · VVOI×exp
(T0 − Tcal
T1/2
· ln2
)
×
(Tacq
T1/2
· ln2
)
×
(
1 − exp
(
−TacqT1/2 · ln2
))−1
,
where VVOI (in mL) is a volume of interest (VOI) placed in the reconstructed image,
T0 is the start time, Tacq is the duration of the acquisition, T1/2 is the half-time of the
radionuclide used, Tcal is the time of the activity calibration, and R (in cps) represents the
counting rate measured in the VOI.
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Volume of interest selection
For phantom and ex vivo studies, we used CT images for VOI selection. The difference
of HU values for water and soft tissue and air provided an opportunity to obtain VOI by
binarization of CT images with an adapted threshold.
For in vivo studies, the separation of kidneys and tumors from surrounding soft tissues
was difficult in CT images. Therefore, the SPECT images were used for the VOI selection.
For kidney studies, we first applied a threshold in SPECT images, and then, as a spill-
out from the PVE would bias this selection, we eroded the VOIs in order to match the
borders in CT images. For the tumor analysis, the threshold in SPECT images cannot be
used in the same manner as the activity distribution was heterogeneous and its border
mismatched the actual tumor borders in anatomical image (Fig. 2). The whole tumor VOI
is presented in Fig. 2 in red and the VOI selected for activity above certain threshold
is shown in green. Such VOIs were selected in SPECT images following these steps: (i)
image with Gaussian filtering with σ of 1.5× (voxel size), (ii) define the threshold as 8% of
a maximum value in a local region in the blurred image, and (iii) dilate the obtained VOI
by 2 voxels. This approach has been approved in kidney images before using it in the final
tumor image analysis.
Gadolinium quantity calculation
The obtained 111In activity measurement from SPECT images was used to find the
equivalent Gd-NP quantity. The coefficient of proportionality between these two values,
αInGd(t), was defined as
αInGd(t) = mGdAIn(t) ,
where mGd is the mass of Gd-NP and AIn(t) is the 111In activity at time t. It could either
be measured or calculated for each injection preparation. In these studies in case of mea-
sured αInGd(t), the activity, AIn(t), was obtained with the Wallac Wizard gamma counter
and the Gd mass, mGd, was determined by ICP-MS. We also used calculated αcalcInGd(t)
Fig. 2 Possible choice of VOI selections. Illustration of in vivo SPECT/CT tumor image with 111In activity (left)
and possible choice of VOI selections (right): total volume of tumor (red) and VOI from SPECT image
containing only radioactivity perfusion region (green)
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coming from the same formula as above from initial proportions of gadolinium mass,
mGd, and 111In activity at preparation time.
In the experiments on phantom tubes, αInGd(t) was obtained on the sample with the
highest concentration and used to calculate the Gd-NP concentration for the three other
tubes. In in vivo kidney studies, several independent samples from the same preparation
as in the main analysis were used to determine αInGd(t) by fitting the linear propor-
tionality between AIn(t) and mGd. In in vivo tumor studies, we also used the calculated
αcalcInGd(t).
Reference measurements for 111In and Gd-NPs
In order to evaluate the SPECT image-based activity quantification, we measured the
reference values on the same Wallac Wizard gamma counter as for the calibration. The
reference values of the Gd masses were obtained with the ICP-MC measurements. This
study was originally made on post mortem animals because the reference values of the
activity could only be measured on extracted organs.
Uncertainties estimation
In order to estimate the uncertainty on the activity measurements we summed up in
quadrature the following individual uncertainties:
– Standard deviation of a count rate in VOI
– Uncertainty on mask selection was taken of 10%
– Uncertainty on activity reference measurement with a gamma counter (2%).
Results
Calibration for 111In quantification
The calibration system volume sensitivity after scatter, attenuation, and PVE corrections
mentioned above was SVol = (2.11±0.04) ·103 cps/MBq. This calibration coefficient was
used for in vitro, in vivo, and ex vivo image quantification.
Phantom studies
Results on image quantification with system volume sensitivity given above is presented
in Fig. 3, where one can observe two sets of points: black for four 111In + Gd-NPs sam-
ples and blue for six 111In without Gd-NPs as explained above. A linear correspondence
between measured and reference activities was established for two independent sets of
measurements (Fig. 3, top). The accuracy shown at the bottom of Fig. 3 is larger than 10%
for activities below 2 MBq. In terms of concentration, it corresponds to 4–8 MBq/mL as
the volumes of images tubes were 250μL and 500 μL.
The calibration coefficient for Gd masses αInGd(timg) was (0.56 ± 0.06) mg/MBq. The
measurements of Gd mass on the 111In + Gd samples are presented in Fig. 4 and show
linear dependence between measured and reference values.
In vivo studies on kidneys
The illustration of the result of SPECT image corrections is presented in Fig. 5, where
one can find SPECT/CT images with no correction, after only scatter corrections, after
scatter and attenuation corrections, and after scatter, attenuation, and PVE corrections.
The last one masks out the activity outside of target VOI.
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Fig. 3 Activity from SPECT images in phantom studies. Activity measured from corrected SPECT images in
phantom studies for 111In + Gd-NPs (black points) and 111In without Gd-NPs (blue points). The error bars for
measured activities are the standard deviations
The results of activity quantification on right kidneys are presented in Fig. 6 for in vivo
and in Fig. 7 for ex vivo studies. In these plots, one can observe that after attenuation,
scatter, and PVE corrections, in vivo quantified activities correspond to their expected
values. However, the total activity in kidneys was below 3.5 MBq while, from the in vitro
tests (Fig. 3), the quantification becomes non-linear below 2 MBq. The in vivo results
also differ from reference within 10% for the activities above 2 MBq, which confirms the
results on tube phantoms.
The result of αInGd(t0) obtained on left kidneys at injection preparation time is pre-
sented in Fig. 8, left. It could be observed that two points are out the general behavior
which is discussed in the “Discussion” section below. We decided to exclude two points
from the linearly fit which were obvious outliers for both kidneys.
The measured αInGd(t0) = (0.76 ± 0.03) μg/MBq at preparation time was recalculated
for in vivo imaging moment. The result of in vivo Gd mass quantification is presented in
Fig. 8, right where Gd quantity obtained from SPECT images were compared to ICP-MS
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Fig. 4 Gadoliniummass from SPECT images in phantom studies. Gadoliniummass measurement from SPECT
images for 111In + Gd phantom samples as a function of expected mass of gadoliniummeasured with ICP-MS
reference measurements. Once again, the two kidneys from the same animals are out of
the linear fit.
In vivo studies on tumors
The results of image-based activity quantification in red-type VOIs and green-type VOIs
from Fig. 2 are presented in Fig. 9, left and middle, correspondingly. The total activity
measured in green-type VOIs for the two highest concentrations is within 10% of the
expected reference value. Ex vivo results on tumors show the accuracy within 5% for the
activities above 1 MBq (Fig. 9, right).
For the Gd mass quantification, we had the reference value only for one point in Figs. 9
at 2.55 MBq. With αInGd(t0) = (0.76 ± 0.03) μg/MBq obtained on left kidneys (Fig. 8,
left), the image-based measurement gave (3.1 ± 0.2) μg while the ICP-MS reference was
(4.58±0.05)μg, which is the same order of magnitude but differs by almost 70%. However,
the αcalcInGd(t0) calculated from the initial proportions of Gd-NPs and 111In was (0.91 ±
0.03) μg/MBq and gave (4.1± 0.2) μg which differs only by 10% from the reference value.
Discussion
In this article, we presented a method for Gd nanoparticle quantification from SPECT
images when they are labeled with 111In. Once all corrections (scatter, attenuation, PVE)
are applied, we showed that image-based SPECT quantification of total Gd mass in
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Fig. 5 Examples of in vivo images. Examples of in vivo images with no corrections(a), after only scatter
corrections(b), after scatter and attenuation corrections(c), and after scatter, attenuation and PVE corrections
(d). The activity outside the target VOI has been masked out during PVE corrections
organs is feasible and could be 10% accurate for the total activities above 2 MBq, i.e.,
4 MBq/mL in terms of concentration. The studies on phantoms supported the hypothesis
that SPECT images could be used for Gd-NP quantification as a linear correspon-
dence between measured from SPECT images and ICP-MS reference masses of Gd was
observed. We obtained ∼ 2 mg/mL of Gd-NP concentration as a lower limit for 10%
accuracy measurements.
The in vivo image quantification of Gd-NPs after scatter, attenuation, and PVE correc-
tions also confirms that hypothesis. Considering the volume of the kidney cortex (the
region where the tracer was mainly accumulated) about 0.7 mL, we obtained the activity
concentration of the same order of magnitude as for phantom experiment: ∼ 3 MBq/mL.
At the injection preparation time, αInGd(t0) was 0.76 ± 0.03 μg/MBq which gives the
detection limit of Gd at the concentration of ∼2 μg/mL which is 3 order of magnitude
lower than in phantom experiment. This shows that by adjusting the In-Gd proportions,
one can choose the detectable concentration of Gd-NPs at least in a range from 1 mg/mL
to 1 μg/mL while keeping the 10% accuracy defined by 111In image-based measurement.
We observed in in vivo studies that two kidney points were out of the linear fit behavior.
It is hypothesized that due to use of DTPA, the different kidneys’ clearance rate of free
Gd and 111In formed during metabolic processes could explain this observation (more
details, for example, in [24]). The same two animals showed this behavior for αInGd(t)
measurement in their left kidneys and also for Gd masses obtained in their right kidneys
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Fig. 6 Activity from SPECT images in in vivo studies (kidneys). In vivo 111In activity measurements on right
kidneys from uncorrected images in black, from images with only attenuation correction in red, with only PVE
corrections in green and with all corrections in blue
which is in line with the hypothesis of different clearance rate for different animals. This
observation revokes the developed SPECT quantification approach as the 111In activity
measured in images is in line with reference values. However, due to indirectness of the
Gd-NP mass quantification, metabolic processes can influence the αInGd(t) and, thus, the
eventual measurement. This means that even if kidneys provide most of the time the
largest image signal, the tests of quantification approaches for Gd quantification should
be done on other organs, preferably on tumors.
The in vivo image quantification on tumors showed the crucial influence of the VOI
choice. We tested methods to define them from anatomical or functional images. We
can conclude that the strategy should be adapted to concrete activity distribution proper-
ties. Also, the in vivo image quantification for Gd-NPs on tumors demonstrated that the
obtained values based on αInGd measured on kidneys were less consistent with expecta-
tion than the result based on αcalcInGd calculated from initial proportions. This is again in
line with a hypothesis about different clearance rate of free Gd and 111In.
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Fig. 7 Activity from SPECT images in ex vivo studies (kidneys). Ex vivo measurements on right kidneys of 111In
activity for uncorrected images in black and with only scatter and attenuation correction in red. The PVE
corrections were not applied as volume of interest containing a kidney, and a formol was large enough to
take into account this effect
All this demonstrates the main limitation of the method. As in vivo Gd measurements
are indirect as one can measure only 111In activities from SPECT images and deduce Gd
masses from them. The coefficient between these two values, αInGd(t), should be precisely
known and that the labeling of 111In and Gd should be stable in time and evacuated simul-
taneously from an organ. Otherwise, the Gd mass measurement from SPECT images
could be unreliable.
An alternative to SPECT imaging for the same aim could be PET as AGuIX nanopar-
ticles can be labeled with 68Ga PET tracer. This modality could potentially be more
precise for image quantification but remains also indirect but probaly is less affected by
methabolism processes as chemical labeling is slightly different. For direct Gd concentra-
tionmeasurements from images, a newmodality, Spectral Photon Counting CT (SPCCT),
could be used [25, 26]. SPCCT is a X-ray tomographic acquisition system using dedicated
detectors in photon-counting mode with energy discrimination. Energy thresholds could
be set such that optimal discrimination of Gd is obtained.
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Fig. 8 Calibration and result for gadolinium mass measurement from SPECT images for in vivo studies
(kidneys) Left: The αInGd(t0) coefficient at injection preparation time for in vivo studies based on left kidneys.
Right: Gadoliniummass measurement from SPECT images for in vivo studies vs. expected mass of gadolinium
measured with ICP-MS in right kidneys. The errors on slope and intercept are only fit errors without taking
into account the systematic uncertainties from SPECT image calibration, Aref and GdICP−MS measurements
During this work, we faced several problems that could be avoided in the future. We
propose several recommendations for protocol developments and tests for in vivo of Gd
quantification methods:
• The chemical bounding of Gd nanoparticles with a radionuclide has to be done
without purification, as this is important for the calculation of the In-Gd coefficient
αInGd(t), which can vary from mg/MBq to μg/MBq.
• Tests of Gd quantification methods of nuclear medicine images done on kidneys are
unreliable as the In-Gd recalculation coefficient αInGd(t) could be modified by
metabolic effects.
• Special care should be taken for VOI definitions. We advise to do a threshold on
anatomical or functional images depending on difference of HU values inside and
outside of VOI in CT images and on the heterogeneity of activity distributions. The
Fig. 9 Activity from SPECT images in in vivo and in ex vivo studies (tumors). The image-based activity
measurements on tumors for uncorrected images (black) and after attenuation correction (red). From left to
right: (1) on in vivo in the red VOI of Fig. 2; (2) on in vivo in the green VOI of Figure 2; (3) on ex vivo
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detailed protocol for the VOI definition is proposed in the “Method and
materials” section.
• The use of formalin should be avoided on ex vivo samples. It makes the testing of
VOI selection difficult as the HU values of formalin is similar to the one of soft
tissues. Additionally, the tests of partial volume effect corrections become impossible.
Moreover, the use of formalin complicates ICP-MS analysis and makes it less
accurate. An alternative for ex vivo sample conservation could be freezing.
Conclusion
In this paper, we studied the potential of SPECT imaging for in vivo quantification
of gadolinium nanoparticles. The main motivation was the possible application of this
method for the treatment planning of radiotherapy enhanced by Gd-NPs. Even if SPECT
image quantification remains technically difficult, it has potential for precise Gd con-
centration measurements. It is indirect, and thus, its accuracy is mainly defined by 111In
image quantification accuracy and the coefficient of proportionality between Gd and
111In. We observed that the accuracy of the 111In image quantification is better than 10%
for activity above 2 MBq or concentrations above ∼ 3–4 MBq/mL. The In-Gd coefficient
to calculate Gd from 111In images may vary at least from mg/MBq to μg/MBq which
defines the Gd-NPs detection limit frommg/mL to μg/mL (from∼2mg/mL to∼2 μg/mL
in this study) with accuracy of 10%.
We showed that the SPECT image quantification method is accurate. However, the
main limitation comes from disproportionality of αInGd in time in different organs. We
assume that the clearance rate of free Gd and 111In formed by metabolic processes could
be different. Therefore, the results obtained in organs in question, such as kidneys, could
be unreliable. Yet, this does not defeat the image-based Gd-NP measurements in tumors
which seems to be unaffected by this problem.
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